300 related articles for article (PubMed ID: 16754847)
1. Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity.
Jinushi M; Hodi FS; Dranoff G
Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9190-5. PubMed ID: 16754847
[TBL] [Abstract][Full Text] [Related]
2. MICA immune complex formed with alpha 3 domain-specific antibody activates human NK cells in a Fc-dependent manner.
Du C; Bevers J; Cook R; Lombana TN; Rajasekaran K; Matsumoto M; Spiess C; Kim JM; Ye Z
J Immunother Cancer; 2019 Aug; 7(1):207. PubMed ID: 31387641
[TBL] [Abstract][Full Text] [Related]
3. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity.
Pende D; Rivera P; Marcenaro S; Chang CC; Biassoni R; Conte R; Kubin M; Cosman D; Ferrone S; Moretta L; Moretta A
Cancer Res; 2002 Nov; 62(21):6178-86. PubMed ID: 12414645
[TBL] [Abstract][Full Text] [Related]
4. MICA/NKG2D-mediated immunogene therapy of experimental gliomas.
Friese MA; Platten M; Lutz SZ; Naumann U; Aulwurm S; Bischof F; Bühring HJ; Dichgans J; Rammensee HG; Steinle A; Weller M
Cancer Res; 2003 Dec; 63(24):8996-9006. PubMed ID: 14695218
[TBL] [Abstract][Full Text] [Related]
5. Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo.
Wiemann K; Mittrücker HW; Feger U; Welte SA; Yokoyama WM; Spies T; Rammensee HG; Steinle A
J Immunol; 2005 Jul; 175(2):720-9. PubMed ID: 16002667
[TBL] [Abstract][Full Text] [Related]
6. CD24 targeting bi-specific antibody that simultaneously stimulates NKG2D enhances the efficacy of cancer immunotherapy.
Han Y; Sun F; Zhang X; Wang T; Jiang J; Cai J; Gao Q; Hezam K; Liu Y; Xie J; Wang M; Zhang J
J Cancer Res Clin Oncol; 2019 May; 145(5):1179-1190. PubMed ID: 30778749
[TBL] [Abstract][Full Text] [Related]
7. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA.
Bauer S; Groh V; Wu J; Steinle A; Phillips JH; Lanier LL; Spies T
Science; 1999 Jul; 285(5428):727-9. PubMed ID: 10426993
[TBL] [Abstract][Full Text] [Related]
8. Human tumor-derived exosomes down-modulate NKG2D expression.
Clayton A; Mitchell JP; Court J; Linnane S; Mason MD; Tabi Z
J Immunol; 2008 Jun; 180(11):7249-58. PubMed ID: 18490724
[TBL] [Abstract][Full Text] [Related]
9. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells.
Carbone E; Neri P; Mesuraca M; Fulciniti MT; Otsuki T; Pende D; Groh V; Spies T; Pollio G; Cosman D; Catalano L; Tassone P; Rotoli B; Venuta S
Blood; 2005 Jan; 105(1):251-8. PubMed ID: 15328155
[TBL] [Abstract][Full Text] [Related]
10. MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma.
Jinushi M; Vanneman M; Munshi NC; Tai YT; Prabhala RH; Ritz J; Neuberg D; Anderson KC; Carrasco DR; Dranoff G
Proc Natl Acad Sci U S A; 2008 Jan; 105(4):1285-90. PubMed ID: 18202175
[TBL] [Abstract][Full Text] [Related]
11. Restoration of antitumor immunity through anti-MICA antibodies elicited with a chimeric protein.
Torres N; Regge MV; Secchiari F; Friedrich AD; Spallanzani RG; Raffo Iraolagoitia XL; Núñez SY; Sierra JM; Ziblat A; Santilli MC; Gilio N; Almada E; Lauche C; Pardo R; Domaica CI; Fuertes MB; Madauss KP; Hance KW; Gloger IS; Zylberman V; Goldbaum FA; Zwirner NW
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32518090
[TBL] [Abstract][Full Text] [Related]
12. Increased Concentrations of Circulating Soluble MHC Class I-Related Chain A (sMICA) and sMICB and Modulation of Plasma Membrane MICA Expression: Potential Mechanisms and Correlation With Natural Killer Cell Activity in Systemic Lupus Erythematosus.
Hervier B; Ribon M; Tarantino N; Mussard J; Breckler M; Vieillard V; Amoura Z; Steinle A; Klein R; Kötter I; Decker P
Front Immunol; 2021; 12():633658. PubMed ID: 34012432
[TBL] [Abstract][Full Text] [Related]
13. NKG2D ligands: unconventional MHC class I-like molecules exploited by viruses and cancer.
Cerwenka A; Lanier LL
Tissue Antigens; 2003 May; 61(5):335-43. PubMed ID: 12753652
[TBL] [Abstract][Full Text] [Related]
14. Interaction of monocytes with NK cells upon Toll-like receptor-induced expression of the NKG2D ligand MICA.
Kloss M; Decker P; Baltz KM; Baessler T; Jung G; Rammensee HG; Steinle A; Krusch M; Salih HR
J Immunol; 2008 Nov; 181(10):6711-9. PubMed ID: 18981088
[TBL] [Abstract][Full Text] [Related]
15. Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104.
Brando C; Mukhopadhyay S; Kovacs E; Medina R; Patel P; Catina TL; Campbell KS; Santoli D
J Leukoc Biol; 2005 Aug; 78(2):359-71. PubMed ID: 15937142
[TBL] [Abstract][Full Text] [Related]
16. Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas.
Jinushi M; Takehara T; Tatsumi T; Hiramatsu N; Sakamori R; Yamaguchi S; Hayashi N
J Hepatol; 2005 Dec; 43(6):1013-20. PubMed ID: 16168521
[TBL] [Abstract][Full Text] [Related]
17. A VEGFR2-MICA bispecific antibody activates tumor-infiltrating lymphocytes and exhibits potent anti-tumor efficacy in mice.
Xu Y; Zhang X; Wang Y; Pan M; Wang M; Zhang J
Cancer Immunol Immunother; 2019 Sep; 68(9):1429-1441. PubMed ID: 31428800
[TBL] [Abstract][Full Text] [Related]
18. Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17.
Chitadze G; Lettau M; Bhat J; Wesch D; Steinle A; Fürst D; Mytilineos J; Kalthoff H; Janssen O; Oberg HH; Kabelitz D
Int J Cancer; 2013 Oct; 133(7):1557-66. PubMed ID: 23526433
[TBL] [Abstract][Full Text] [Related]
19. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.
Armeanu S; Bitzer M; Lauer UM; Venturelli S; Pathil A; Krusch M; Kaiser S; Jobst J; Smirnow I; Wagner A; Steinle A; Salih HR
Cancer Res; 2005 Jul; 65(14):6321-9. PubMed ID: 16024634
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological significance of major histocompatibility complex class I-related chain a and B expression in thyroid cancer.
Xu X; Rao G; Gaffud MJ; Ding HG; Maki G; Klingemann HG; Groh V; Spies T; Caillat-Zucman S; Gattuso P; Plate J; Prinz RA
J Clin Endocrinol Metab; 2006 Jul; 91(7):2704-12. PubMed ID: 16621903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
